1.
Evidence that independent gut‐to‐brain and brain‐to‐gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1‐year population‐based prospective study...
by Koloski, N. A.
Alimentary pharmacology & therapeutics, 2016-09, Vol.44 (6), p.592-600
2.
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)
by Kowal-Bielecka, O
Annals of the Rheumatic Diseases, 2009-05, Vol.68 (5), p.620-34
3.
The London Classification of gastrointestinal neuromuscular pathology: report on behalf of the Gastro 2009 International Working Group
by Knowles, Charles H
Gut, 2010-07, Vol.59 (7), p.882-887
4.
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial
by Aluwini, Shafak, Dr
The lancet oncology, 2015, Vol.16 (3), p.274-283
5.
Common variable immunodeficiency: a new look at an old disease
by Park, Miguel A, MD
The Lancet (British edition), 2008, Vol.372 (9637), p.489-502
6.
9. Food allergy
by Sicherer, Scott H
Journal of allergy and clinical immunology, 2006, Vol.117 (2), p.S470-S475
7.
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomis...
by de Boer, Stephanie M, Dr
The lancet oncology, 2016, Vol.17 (8), p.1114-1126
8.
Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer
by Andreyev, H Jervoise N
Gut, 2012-02, Vol.61 (2), p.179-192
9.
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
by Hapani, Sanjaykumar, MD
The lancet oncology, 2009, Vol.10 (6), p.559-568
10.
Fabry disease: guidelines for the evaluation and management of multi-organ system involvement
by Eng, Christine M
Genetics in medicine, 2006-09, Vol.8 (9), p.539-548
11.
Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients
by Andreyev, Jervoise, Dr
The lancet oncology, 2007, Vol.8 (11), p.1007-1017
12.
Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial
by Glover, Mark, MFOM
The lancet oncology, 2016, Vol.17 (2), p.224-233
13.
Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection
by Bavishi, C.
Alimentary pharmacology & therapeutics, 2011-12, Vol.34 (11‐12), p.1269-1281
14.
Ethanol metabolism and its effects on the intestinal epithelial barrier
by Elamin, E.E
Nutrition reviews, 2013-01-01, Vol.71 (7), p.483-499
15.
Pompe disease diagnosis and management guideline
by Kishnani, Priya S
Genetics in medicine, 2006-05, Vol.8 (5), p.267-288
16.
Epidural technique for postoperative pain: gold standard no more?
by Rawal, Narinder
Regional anesthesia and pain medicine, 2012-05, Vol.37 (3), p.310-317
17.
Review article: the aetiology, diagnosis, mechanisms and clinical evidence for food intolerance
by Lomer, M. C. E.
Alimentary pharmacology & therapeutics, 2015-02, Vol.41 (3), p.262-275
18.
Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
by Moinzadeh, Pia
Annals of the rheumatic diseases, 2015-04, Vol.74 (4), p.730-737
19.
Gastrointestinal Manifestations of STAT3-Deficient Hyper-IgE Syndrome
by Arora, Manish
Journal of clinical immunology, 2017-08-13, Vol.37 (7), p.695-700
20.
Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract
by Simon, Dagmar, MD
Journal of allergy and clinical immunology, 2010, Vol.126 (1), p.3-13
